Table 2.
Results from Five Published Clinical Trials
| Trial Acronym | Experimental Treatment | Control Treatment | Patient Population | Endpoint | Sample Size | Endpoint Number and Rate |
Discontinuation Number and Rate |
Hazard Ratio Associated with Non-compliance | p-value |
| SOLVD-T | Enalapril | Placebo | Left Ventricular Dysfunction with Overt Heart Failure | Total Mortality | 2,569 | 961 (37.4%) | 839 (32.7%) | 2.7 | < 0.0001 |
| SOLVD-P | Enalapril | Placebo | Left Ventricular Dysfunction without Overt Heart Failure | Total Mortality | 4,228 | 638 (15.1%) | 987 (23.3%) | 3.2 | < 0.0001 |
| RENAAL | Losartan | Placebo | Type 2 Diabetes with Nephropathy | Doubling of Serum Creatinine, End-Stage Renal Disease or Death | 1,513 | 686 (45.3%) | 469 (31.0%) | 2.6 | < 0.0001 |
| LIFE | Losartan | Atenolol | Hypertension and Left Ventricular Hypertrophy | Myocardial Infarction, Stroke or Cardiovascular Death | 9,193 | 1096 (11.9%) | 2,273 (24.7%) | 2.6 | < 0.0001 |
| OPTIMAAL | Losartan | Captopril | High-Risk Acute Myocardial Infarction | Total Mortality | 5,477 | 946 (17.3%) | 1,156 (21.1%) | 5.0 | < 0.0001 |